High expression of ETS2 predicts poor prognosis in acute myeloid leukemia and may guide treatment decisions.

ABSTRACT:

Background

ETS2 is a downstream effector of the RAS/RAF/ERK pathway, which plays a critical role in the development of malignant tumor. However, the clinical impact of ETS2 expression in AML remains unknown.

Methods

In this study, we evaluated the prognostic significance of ETS2 expression using two relatively large cohorts of AML patients.

Results

In the first cohort, compared to low expression of ETS2 (ETS2 ^low), high expression of ETS2 (ETS2 ^high) showed significant shorter OS, EFS and RFS in the current treatments including the allogeneic HCT group (n = 72) and the chemotherapy group (n = 100). Notably, among ETS2 ^high patients, those received allogeneic HCT had longer OS, EFS and RFS than those with chemotherapy alone (allogeneic

SUBMITTER: Fu L 

PROVIDER: S-EPMC5518161 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature